Santhera Shores Up Finances With Chiesi Deal for Raxone
Executive Summary
In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.